Illumina, Inc. (ILMN) is a leading global company in the bioinformatics and genomics industry, headquartered in San Diego, California. Founded in 1998, it specializes in the development, manufacturing, and marketing of integrated systems for the analysis of genetic variations and biological functions.
The products that Illumina offers are used in numerous areas such as research on diseases, pharmaceutical drug discovery, and genetic profiling for personalized medicine. Its technologies have also brought about a revolution in large-scale genome sequencing, allowing for rapid and accurate results.
Illumina's innovative suite of technologies, instruments and consumables, including the popular NovaSeq series, have transformed genetic sequencing, making it not only more affordable but also more accessible to the broader scientific community. Illumina's sequencers can read and analyze millions of DNA strings in parallel, drastically reducing the time and cost associated with decoding human DNA.
The company has adopted a dynamic business model, incorporating both product sales, which includes its sequencing platforms and consumables, and service revenue which includes sequencing and genotyping services.
However, Illumina is not solely focused on the commercial sector. The company has positioned itself as a vital player in public health, playing a significant role in the research, understanding, and monitoring of Covid-19, among other global health concerns.
Illumina's prominence as a key industry player has been demonstrated through its consistently strong performance in the stock market. In 2020, Illumina reported revenues of $3.24 billion. It is listed on the NASDAQ stock exchange under the ticker symbol "ILMN".
In a rapidly evolving industry, Illumina has managed to stay at the forefront through a commitment to innovation and a dedication to aiding scientific research. It has resulted in numerous successful collaborations across the health care, crop science, and animal health sectors.
Though Illumina operates in an industry which is highly technical and incredibly complex, it is guided by a principle that is surprisingly simple and profoundly impactful: unlocking the power of the genome. As the company continues its journey, Illumina's contributions are sure to remain vital in the understanding and application of genomics going forward.